Exclusive Summary

• Palonosetron's global patents have expired, allowing for low market entry barriers and ripe opportunities for generic drug distribution, backed by quality assurance from consistency evaluation in China.
• The substantial global patient population suffering from chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) ensures robust market demand, with palonosetron being a first-line treatment recommended by clinical guidelines.
• In-house API production and Tier B medical insurance classification provide significant cost advantages and market competitiveness, facilitating overseas market expansion.
• The company's willingness and experience in international collaboration enable quick partnerships with overseas pharmaceutical companies through distribution models to capture market share.
• The product's flexible dosages (0.25mg and 0.075mg) cater to diverse clinical needs and administration protocols.

Asset Materials

Contact Us for Full Materials